Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared an article by Wan-Qin Chong on X:
“Randomized phase II study in The Lancet Oncology shows that adding bevacizumab to pembrolizumab in previously treated nasopharygeal carcinoma improves RR (58.3% vs 12.5%) and significantly increased PFS to 13.8m from 1.6m: HR 0.25!”
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.
Authors: Wan-Qin Chong, et al.
More posts featuring Stephen V Liu.